182 related articles for article (PubMed ID: 2889081)
21. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
22. A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therapy in chronic hepatitis B virus infection. A preliminary analysis of the first 32 patients.
Alexander GJ; Fagan EA; Guarner P; Rolando N; Brahm J; Eddleston AL; Williams R
J Hepatol; 1986; 3 Suppl 2():S183-8. PubMed ID: 3298406
[TBL] [Abstract][Full Text] [Related]
23. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
24. Human lymphoblastoid and fibroblast interferon in the treatment of chronic hepatitis B.
Hayashi J; Noguchi A; Nakashima K; Hayashi S; Kashiwagi S; Mayumi T; Motomura M
Clin Ther; 1990; 12(1):12-21. PubMed ID: 2328524
[TBL] [Abstract][Full Text] [Related]
25. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.
Fattovich G; Brollo L; Boscaro S; Pontisso P; Giustina G; Criscuolo D; Maladorno D; Alberti A; Realdi G; Ruol A
J Hepatol; 1989 Nov; 9(3):331-7. PubMed ID: 2691568
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic effects of human leukocyte interferon on chronic active hepatitis B in children.
Hashida T; Sawada T; Esumi N; Kinugasa A; Kusunoki T; Kishida T
J Pediatr Gastroenterol Nutr; 1985 Feb; 4(1):20-5. PubMed ID: 3981364
[TBL] [Abstract][Full Text] [Related]
27. Treatment of hepatitis B surface antigen carriers in the early stage of the infection using recombinant alpha-interferon with steroid priming.
Guan R; Ho KY; Yap I; Kang JY; Tan CC; Ng C; Smith R; Wee A
Aliment Pharmacol Ther; 1995 Oct; 9(5):535-40. PubMed ID: 8580274
[TBL] [Abstract][Full Text] [Related]
28. Interferon treatment of chronic hepatitis B surface antigen (HBsAg) carriers. A description of the activation profiles of natural killer cells obtained with different schedules of administration in three subsets of carriers.
Actis GC; Maran E; Saracco G; Rosina F; Brunetto MR; Baldi M; Lattore V; Rocca G; Bonino F; Rizzetto M
Ric Clin Lab; 1987; 17(4):331-41. PubMed ID: 3438668
[TBL] [Abstract][Full Text] [Related]
29. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA.
Ip HM; Lelie PN; Wong VC; Kuhns MC; Reesink HW
Lancet; 1989 Feb; 1(8635):406-10. PubMed ID: 2563788
[TBL] [Abstract][Full Text] [Related]
30. Treatment of chronic hepatitis B with human lymphoblastoid interferon: results of a controlled trial.
Mazzella G; Villanova N; Abdu-Ahmed M; Barbara L; Saracco G; Rizzetto M; Cancellieri C; Roda E
Chemioterapia; 1988 Dec; 7 Suppl 3():12-4. PubMed ID: 3073868
[TBL] [Abstract][Full Text] [Related]
31. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon.
Lin CY
Kidney Int; 1995 Jan; 47(1):225-30. PubMed ID: 7731150
[TBL] [Abstract][Full Text] [Related]
32. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
33. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.
Alexander GJ; Brahm J; Fagan EA; Smith HM; Daniels HM; Eddleston AL; Williams R
Lancet; 1987 Jul; 2(8550):66-9. PubMed ID: 2885573
[TBL] [Abstract][Full Text] [Related]
34. Interferon alfa-2b therapy in children with chronic hepatitis B.
Sokal EM; Wirth S; Goyens P; Depreterre A; Cornu C
Gut; 1993; 34(2 Suppl):S87-90. PubMed ID: 8314496
[TBL] [Abstract][Full Text] [Related]
35. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
36. Interferon for hepatitis B: US experience.
Perrillo RP
Gut; 1993; 34(2 Suppl):S95-6. PubMed ID: 8314498
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection.
Lok AS; Lai CL; Wu PC; Leung EK
Lancet; 1988 Aug; 2(8606):298-302. PubMed ID: 2899719
[TBL] [Abstract][Full Text] [Related]
38. Interferon treatment of anti-HBe positive and HBV DNA positive chronic hepatitis B.
Alberti A; Fattovich G; Pontisso P; Brollo L; Belussi F; Ruol A
Chemioterapia; 1988 Dec; 7 Suppl 3():15-9. PubMed ID: 3073869
[TBL] [Abstract][Full Text] [Related]
39. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA
Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667
[TBL] [Abstract][Full Text] [Related]
40. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
